We are delighted to share an opportunity from our partners at Global Resource for Advancing Cancer Education’s (GRACE). If you are coping with cancer and interested in the latest in targeted therapy research, you wont want to miss this event!
Researchers are making advances in molecularly-driven lung cancer seemingly every day. The need for patient education is on-going and ALK+, ROS1, and EGFR lung cancer patients actively seek it.
They will find it at the Global Resource for Advancing Cancer Education’s (GRACE) 2015 Acquired Resistance for Targeted Therapies in Lung Cancer Patient Forum. The event will take place Saturday, Oct. 3, 2015, at the Marriott Waterfront San Francisco.
Patients and their caregivers who attend will hear directly from leaders in targeted therapy research. In addition to presentations and question and answer sessions, attendees will have many opportunities to approach the faculty to speak with them directly. An evening reception after the event will enable additional one-on-ones and give attendees – many of whom know each other from online support groups – a chance to meet in real life.
- Acquired Resistance & Why It Occurs
- Brain as a Sanctuary Site
- Repeat Biopsies and Serum-Based Testing
- Selecting Patients for Immunotherapy
- Quality of Life vs Progression Free Survival – What Are the Most Relevant Endpoints?
- Patient Assistance Programs
- Lung Cancer Survivorship
Additionally, breakouts for ALK/ROS1 patients and EGFR patients will cover issues specific to those patients:
- New Ideas and Treatment Options
- Individual Treatments for Individual Mutations
- Combinations to Prevent & Treat Acquired Resistance
- Drug Sequencing
Registration is $25 per person.
GRACE has negotiated a group rate for rooms at the Marriott Waterfront San Francisco of $179 per night (request the “GRACE Patient Forum” room rate).
View the agenda for additional details and a list of confirmed faculty.
To learn more about GRACE, visit us at www.cancerGRACE.org.
We recently were introduced to a group that has found a creative way for individuals to help fund cancer research. moleCures(mol-e-cures), is a new crowdfunding platform that connects donors directly to researchers to fast track funding to ground breaking innovation.
Similar to Kickstarter or our friends at GiveForward, crowdfunding is a way to raise monetary contributions from a large number of people (crowd) via the internet towards a common goal, service, project, etc. This method of raising funds has been very successful and continues to grow with viral trends of social media and word of mouth.
moleCures is unique due to the credibility and choice it offers.
CREDIBILITY: moleCures takes the time to vet all of the research projects with researchers from accredited academic research institutions who have published peer reviewed studies so that donors can feel confident that their research dollars are going directly to a credible research project. What’s even better? The research projects will take place once it’s been funded so there’s transparency and a direct impact from the donation dollars.
CHOICE: moleCures also offers donors the opportunity to donate directly or create a campaign to fundraise for a research project of their own choice. Creating a campaign is a meaningful way to share their donor story. Whether you’ve lost loved ones to cancer or would like to raise money in behalf of yourself, someone, or a foundation, you can fully customize your campaign page and tell your story.
Learn more about the current research projects from Harvard/Brigham and Women’s hospital . The researchers are inspired by helping and saving patients and could use your support. Make a difference by donating, campaigning, or simply spreading the word over social media.
Like what moleCures is doing? More research projects and events will be coming soon. Stay connected with moleCures by following on Twitter or liking on Facebook.
DISCLAIMER: This post is designed to provide general information on the topics presented. Triage Cancer is not endorsing the organization(s) mentioned in any way.